CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results

CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results San Diego, CA - August 13, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ext

Event · Earnings
Original reporting
Published Aug 13, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CVSI
Bearish
medium confidence
Mentioned
$CVSI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CVSIBearishMed
01

Why it matters

Q2 2026 results show revenue pressure and continued losses, while management attributes the decline to restrictive federal and state regulations. The company also emphasizes expense reductions and product/e-commerce expansion, but the cash balance is low.

02

Market read

Traders can update CVSI’s near-term fundamentals using the newly disclosed quarterly revenue, margin, operating expense reductions, adjusted EBITDA loss, and cash balance, plus the regulatory delay narrative.

03

What to watch

The excerpt notes 44% of net revenue came from new products launched since 2023 and that a new e-commerce platform (PlusHLTH.com) launched, which could support future conversion even if Q2 was weak.

Relevance 7/10Novelty 7/10Timing: after-hours filing, with a results call scheduled for 4:30 pm EDT

Background

CV Sciences is an OTC-listed consumer wellness company focused on hemp extracts and related wellness products, with recent results framed around regulatory constraints.

Company-level read

Ticker impact

$CVSIBearishMedium confidence
Context

CV Sciences reported Q2 2026 revenue of $3.0M, down from $3.6M a year ago, citing restrictive hemp regulations impacting sales volume.

Expected impact

Likely bearish bias for the next session as traders weigh declining revenue, negative adjusted EBITDA, and low cash ($0.3M).

Evidence & confidence

This is a primary 8-K earnings-style disclosure with multiple concrete negatives (revenue decline, operating loss, adjusted EBITDA loss, cash balance) and a clear driver (regulatory restrictions). However, no guidance or balance-sheet financing details are included in the excerpt, limiting conviction on magnitude of repricing.

Market effects

Highlights ongoing regulatory overhang for hemp-derived cannabinoid products, which can pressure demand and unit sales for similarly positioned nutraceutical firms.

No clear regional transmission beyond US regulatory impact mentioned.

Limited, as the cited regulatory driver is US federal and certain state restrictions.

Counterpoint

Gross margin stayed relatively stable (48.6% vs 48.9% sequentially) and operating expenses fell, suggesting cost discipline could offset some revenue pressure if regulations ease.

Key entities

  • CV Sciences, Inc.

    Subject of the 8-K, reporting Q2 2026 financial results and operational/regulatory highlights.

  • U.S. Senate

    Voted to approve a continuing resolution delaying restrictive provisions for hemp-derived cannabinoid products, per the filing.

Related articles

$CVSIMed

CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results

CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results San Diego, CA - November 12, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ex

$SLNHMed

Soluna Q3 Earnings Call Highlights

Soluna reported a Q3 gross loss of $1.9M, impacted by $3M in wind turbine repairs. Revenue was $12.4M, with mining revenue down 33%. The company has $109.3M in cash and $7.7M in debt post-repayment. Soluna formed a joint venture with Applied Digital for a 50MW facility, with closing expected by early December. Future AI projects may use 70-80% debt financing.

$NIUMed

Niu Tech (NIU) Q3 2026 Earnings Call Transcript

Niu Tech (NIU) reported Q3 2026 earnings, with total sales volume up 15.4% YoY to 534,057 units. Revenue was RMB 1.71 billion, up 1.2% YoY. China sales grew 8.6% YoY, while international sales surged 226%. Gross margin expanded to 18.0%. The company highlighted strong growth in electric motorcycles, which accounted for 56% of China sales, and strategic product launches.